These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 12611456)

  • 41. Predictive value of (99m)Tc sestamibi scintigraphy in the evaluation of doxorubicin based chemotherapy response in patients with advanced breast cancer.
    Alonso O; Delgado L; Núñez M; Vargas C; Lopera J; Andruskevicius P; Sabini G; Gaudiano J; Musé IM; Roca R
    Nucl Med Commun; 2002 Aug; 23(8):765-71. PubMed ID: 12124482
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Twenty-one-gene recurrence score assay in BRCA-associated versus sporadic breast cancers: Differences based on germline mutation status.
    Shah PD; Patil S; Dickler MN; Offit K; Hudis CA; Robson ME
    Cancer; 2016 Apr; 122(8):1178-84. PubMed ID: 26859126
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Contribution of epigenetic alteration of BRCA1 and BRCA2 genes in breast carcinomas in Tunisian patients.
    Ben Gacem R; Hachana M; Ziadi S; Amara K; Ksia F; Mokni M; Trimeche M
    Cancer Epidemiol; 2012 Apr; 36(2):190-7. PubMed ID: 21978880
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Homologous recombination deficiency (HRD) status predicts response to standard neoadjuvant chemotherapy in patients with triple-negative or BRCA1/2 mutation-associated breast cancer.
    Telli ML; Hellyer J; Audeh W; Jensen KC; Bose S; Timms KM; Gutin A; Abkevich V; Peterson RN; Neff C; Hughes E; Sangale Z; Jones J; Hartman AR; Chang PJ; Vinayak S; Wenstrup R; Ford JM
    Breast Cancer Res Treat; 2018 Apr; 168(3):625-630. PubMed ID: 29275435
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Relative dose intensity as a proxy measure of quality and prognosis in adjuvant chemotherapy for breast cancer in daily clinical practice.
    Schraa SJ; Frerichs KA; Agterof MJ; Hunting JCB; Los M; de Jong PC
    Eur J Cancer; 2017 Jul; 79():152-157. PubMed ID: 28494406
    [TBL] [Abstract][Full Text] [Related]  

  • 46. BRCA1/BRCA2 germline mutations in locally recurrent breast cancer patients after lumpectomy and radiation therapy: implications for breast-conserving management in patients with BRCA1/BRCA2 mutations.
    Turner BC; Harrold E; Matloff E; Smith T; Gumbs AA; Beinfield M; Ward B; Skolnick M; Glazer PM; Thomas A; Haffty BG
    J Clin Oncol; 1999 Oct; 17(10):3017-24. PubMed ID: 10506595
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Phenotypic analysis of familial breast cancer: comparison of BRCAx tumors with BRCA1-, BRCA2-carriers and non-familial breast cancer.
    Aloraifi F; Alshehhi M; McDevitt T; Cody N; Meany M; O'Doherty A; Quinn CM; Green AJ; Bracken A; Geraghty JG
    Eur J Surg Oncol; 2015 May; 41(5):641-6. PubMed ID: 25736863
    [TBL] [Abstract][Full Text] [Related]  

  • 48. BRCA1-like profile is not significantly associated with survival benefit of non-myeloablative intensified chemotherapy in the GAIN randomized controlled trial.
    van Rossum AGJ; Schouten PC; Weber KE; Nekljudova V; Denkert C; Solbach C; Köhne CH; Thomssen C; Forstbauer H; Hoffmann G; Kohls A; Schmatloch S; Schem C; von Minckwitz G; Karn T; Möbus VJ; Linn SC; Loibl S; Marmé F
    Breast Cancer Res Treat; 2017 Dec; 166(3):775-785. PubMed ID: 28822007
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy.
    Petit T; Wilt M; Velten M; Millon R; Rodier JF; Borel C; Mors R; Haegelé P; Eber M; Ghnassia JP
    Eur J Cancer; 2004 Jan; 40(2):205-11. PubMed ID: 14728934
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Risk of breast cancer recurrence and contralateral breast cancer in relation to BRCA1 and BRCA2 mutation status following breast-conserving surgery and radiotherapy.
    Kirova YM; Stoppa-Lyonnet D; Savignoni A; Sigal-Zafrani B; Fabre N; Fourquet A;
    Eur J Cancer; 2005 Oct; 41(15):2304-11. PubMed ID: 16140006
    [TBL] [Abstract][Full Text] [Related]  

  • 51. TBX2 is preferentially amplified in BRCA1- and BRCA2-related breast tumors.
    Sinclair CS; Adem C; Naderi A; Soderberg CL; Johnson M; Wu K; Wadum L; Couch VL; Sellers TA; Schaid D; Slezak J; Fredericksen Z; Ingle JN; Hartmann L; Jenkins RB; Couch FJ
    Cancer Res; 2002 Jul; 62(13):3587-91. PubMed ID: 12097257
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Breast cancer after mantle irradiation for Hodgkin's disease: correlation of clinical, pathologic, and molecular features including loss of heterozygosity at BRCA1 and BRCA2.
    Gaffney DK; Hemmersmeier J; Holden J; Marshall J; Smith LM; Avizonis V; Tran T; Neuhausen SL
    Int J Radiat Oncol Biol Phys; 2001 Feb; 49(2):539-46. PubMed ID: 11173152
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Function of BRCA1 and BRCA2 genes associated with hereditary predisposition to breast cancer].
    Jasińska A; Krzyzosiak WJ
    Postepy Biochem; 2001; 47(2):146-59. PubMed ID: 11757317
    [No Abstract]   [Full Text] [Related]  

  • 54. Predictive value of MGMT, hMLH1, hMSH2 and BRCA1 protein expression for pathological complete response to neoadjuvant chemotherapy in basal-like breast cancer patients.
    Nakai K; Mitomi H; Alkam Y; Arakawa A; Yao T; Tokuda E; Saito M; Kasumi F
    Cancer Chemother Pharmacol; 2012 Apr; 69(4):923-30. PubMed ID: 22083523
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Her-2/neu expression as a predictive factor for response to anthracycline-based chemotherapy in a mexican population of locally advanced breast cancer patients.
    Muñoz-Gonzalez D; Zeichner-Gancz I; Candelaria M; Ramirez-Ugalde MT; Perez-Sanchez M; Cervantes-Vazquez G; Cantu-de Leon D; Mora-Tizcareño A; Leonor-Ortíz J
    Med Oncol; 2005; 22(1):23-8. PubMed ID: 15750193
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Should knowledge of BRCA1 status impact the choice of chemotherapy in metastatic breast cancer: a review].
    Clergue O; Jones N; Sévenet N; Quenel-Tueux N; Debled M
    Bull Cancer; 2015 Mar; 102(3):245-55. PubMed ID: 25758301
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Expression of M2 macrophage markers YKL-39 and CCL18 in breast cancer is associated with the effect of neoadjuvant chemotherapy.
    Litviakov N; Tsyganov M; Larionova I; Ibragimova M; Deryusheva I; Kazantseva P; Slonimskaya E; Frolova I; Choinzonov E; Cherdyntseva N; Kzhyshkowska J
    Cancer Chemother Pharmacol; 2018 Jul; 82(1):99-109. PubMed ID: 29728799
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A significant response to neoadjuvant chemotherapy in BRCA1/2 related breast cancer.
    Chappuis PO; Goffin J; Wong N; Perret C; Ghadirian P; Tonin PN; Foulkes WD
    J Med Genet; 2002 Aug; 39(8):608-10. PubMed ID: 12161606
    [No Abstract]   [Full Text] [Related]  

  • 59. Neoadjuvant triweekly nanoparticle albumin-bound paclitaxel followed by epirubicin and cyclophosphamide for Stage II/III HER2-negative breast cancer: evaluation of efficacy and safety.
    Shimada H; Ueda S; Saeki T; Shigekawa T; Takeuchi H; Hirokawa E; Sugitani I; Sugiyama M; Takahashi T; Matsuura K; Yamane T; Kuji I; Hasebe T; Osaki A
    Jpn J Clin Oncol; 2015 Jul; 45(7):642-9. PubMed ID: 25989989
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Epirubicin With Cyclophosphamide Followed by Docetaxel With Trastuzumab and Bevacizumab as Neoadjuvant Therapy for HER2-Positive Locally Advanced Breast Cancer or as Adjuvant Therapy for HER2-Positive Pathologic Stage III Breast Cancer: A Phase II Trial of the NSABP Foundation Research Group, FB-5.
    Smith JW; Buyse ME; Rastogi P; Geyer CE; Jacobs SA; Patocskai EJ; Robidoux A; Conlin AK; Ansari B; Keogh GP; Stella PJ; Gross HM; Lord RS; Polikoff JA; Mauquoi C; Mamounas EP; Swain SM; Wolmark N
    Clin Breast Cancer; 2017 Feb; 17(1):48-54.e3. PubMed ID: 27693116
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.